The Vancouver-based company’s device is designed to treat refractory angina. The article, published in the Journal of the American College of Cardiology: Cardiovascular Interventions, featured a 66 year old man with angina who was treated with anti-ischemic therapy.
Four months after being implanted with the Reducer, the patient was asymptomatic for angina and reported improved quality of life, according to Neovasc.
A four-month dipyridamole stress perfusion CMR revealed an ischemic burden of 13.3%, down from 22.9%, and a global myocardial perfusion reserve index of 1.61, up from 1.25.
“The authors of this article point to objective evidence available via stress perfusion CMR, providing insights into the potential impact of the Reducer on the ischemic burden, suggesting a physiological rationale as to how the Reducer reduces a perfusion defect in this patient,” Neovasc’s president & CEO, Fred Colen, said in prepared remarks.
“Stress perfusion CMR is emerging as the noninvasive gold standard for the assessment of ischemia. We believe the use of a reliable, non-operator-dependent imaging tool, such as stress perfusion CMR, will allow for greater insights into the potential impact of the Reducer on the ischemic burden of patients with refractory angina with coronary artery disease,” Colen added.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.